WO2004089418A1 - A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid - Google Patents

A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid Download PDF

Info

Publication number
WO2004089418A1
WO2004089418A1 PCT/NL2004/000252 NL2004000252W WO2004089418A1 WO 2004089418 A1 WO2004089418 A1 WO 2004089418A1 NL 2004000252 W NL2004000252 W NL 2004000252W WO 2004089418 A1 WO2004089418 A1 WO 2004089418A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
group
steroidal
acid
cyclodextrins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2004/000252
Other languages
French (fr)
Inventor
Manoj Mazhuvancheril Babu
Tapan Nirranjan Godiwala
Robert Peter Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/413,045 external-priority patent/US20040202687A1/en
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to EP04727461A priority Critical patent/EP1613356A1/en
Priority to MXPA05011115A priority patent/MXPA05011115A/en
Priority to JP2006507868A priority patent/JP2006523687A/en
Priority to US10/552,477 priority patent/US20070049552A1/en
Priority to CA002522115A priority patent/CA2522115A1/en
Publication of WO2004089418A1 publication Critical patent/WO2004089418A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to liquid formulations, in particular pharmaceutical formulations, containing fluoroquinolone antibacterial agents such as ciprofloxacin, and methods of making the same.
  • Ciprofloxacin (l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-7-(l- piperazinyl) -3- quinolinecarboxylic acid) is a fluoroquinolone widely used in the treatment of bacterial infections (Rookaya Mather et al, American Journal of Ophthalmology, Vol. 133, No. 4, p463-466, 2002; P. C. Appelbaum et al, International Journal of Antimicrobial Agents, 16, 2000, p5-15).
  • Fluoroquinolone antibacterial agents such as ciprofloxacin agents are preferred due to, among other reasons, their low MIC 9 o's compared with conventional antibiotics and slower formation of resistant bacterial strains against them.
  • the MIC 90 of ciprofloxacin is generally around 0.5 ⁇ g/g whereas the MIC 0 of gentamicin is 10 ⁇ g/gm (Tai-Lee Ke et al, Journal of Ocular Pharmacology and Therapeutics, Vol. 17, No. 6, p555-562, 2001).
  • Ciprofloxacin is widely used in treatment of bacterial conjunctivitis of the eye and for treatment of corneal ulcers (Physicians Desk Reference; Steven J. Lichenstein, Contemporary Pediatrics, 2002, pl6-19).
  • the chemical structure of ciprofloxacin is:
  • Ciprofloxacin is soluble in dilute (0.1N) hydrochloric acid and is practically insoluble in water and ethanol.
  • the aqueous solubility of ciprofloxacin is 79 ⁇ g/mL (Danna L. Ross et al, International Journal of Pharmaceutics, 63 (1990), 237-250).
  • an acidic buffer is employed at pH 4.5.
  • Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for pharmaceutical administration has been disclosed by Stella et al. in US patent 5,134,127 ('127 patent). Particular examples are sulfoalkylether cyclodextrins combined with various drugs, as 'host- guest' complexes. Exemplification has been achieved by the use of sulfoalkylether cyclodextrins in combination with digoxin, progesterone and testosterone. Among other things, this patent requires that the inclusion (clathrate complex) be formed prior to formulation.
  • Patent No. 6,046,177 both by Stella et al., disclose the use of sulfoalkylether cyclodextrin based solid pharmaceutical formulations and their use.
  • the composition comprises of a physical mixture of a sulfoalkylether cyclodextrin with a therapeutic agent, a major portion of which is not complexed to the cyclodextrin.
  • US Patent No. 5,855,916 to Chiesi describes the formation of soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin demonstrating enhanced water solubility.
  • Exemplifications in the '916 patent include terfenadine, cinnarizine, domperidone, astemizole, ketoconazole, tamoxifene, clomifene and itraconazole as base type drugs.
  • PCT Application WO02/39993 describes a clear solution or gel preparation of a combination drug comprising an anti-inflammatory agent such as a corticosteroid, an anti-infective agent such as a fluoroquinolone a complexation- enhancing polymer, and a solubilizer exhibiting an inclusion phenomenon.
  • an anti-inflammatory agent such as a corticosteroid
  • an anti-infective agent such as a fluoroquinolone a complexation- enhancing polymer
  • a solubilizer exhibiting an inclusion phenomenon.
  • a first aspect of the present invention is an aqueous pharmaceutical composition
  • a fluoroquinolone active agent such as ciprofloxacin, cyclodextrin, a hydroxy acid, and water, the composition preferably having a pH between 4 and 7.
  • the composition further comprises or consists essentially of a soluble polymer.
  • the composition further includes a steroidal or non-steroidal anti-inflammatory agent.
  • the composition further comprises or consists essentially of another co-solubilizer such as a vitamin E derivative, detergents such as Tweens or pluronics, etc.
  • another co-solubilizer such as a vitamin E derivative, detergents such as Tweens or pluronics, etc.
  • compositions of the present invention are useful, among other things, for topical applications (e.g., to the eye, ear/ear passages, nose/nasal passages, etc.) and injectable applications (e.g., for subcutaneous, intramuscular, or intraperitoneal injection, etc.).
  • a second aspect of the present invention is a method of treating a bacterial infection and/or inflammation of an eye of a subject in need thereof, comprising topically administering a formulation as described above to the eye of the subject in an amount effective to treat the bacterial infection and/or inflammation.
  • a further aspect of the present invention is a method of treating a bacterial infection and/or inflammation of a topical surface of a subject such as an ear, nose or other skin surface need thereof, comprising topically administering a formulation as described above to the eye of the topical surface of subject in an amount effective to treat the bacterial infection and/or inflammation.
  • a further aspect of the present invention is an improved method of topically applying a pharmaceutical composition containing an active compound such as ciprofloxacin or other fluoroquinolone active agent to the eye of a subject in need thereof, which active compound precipitates from said composition on the eye, such as on the cornea, of the subject, the improvement comprising including a soluble polymer in said composition in an amount effective to reduce the precipitation of the active compound on the cornea of the subject.
  • an active compound such as ciprofloxacin or other fluoroquinolone active agent
  • a still further aspect of the present invention is an improved topical pharmaceutical composition containing an active compound (such as ciprofloxacin or other fluoroquinolone) used to topically apply said active compound to the eye of a subject in need thereof, which active compound precipitates from the composition on the eye or cornea of the subject, the improvement comprising including from 0.05 to 5% by weight of a soluble polymer in the composition to reduce the precipitation of the active compound on the eye or cornea of the subject.
  • an active compound such as ciprofloxacin or other fluoroquinolone
  • FIGURES Figure 1 shows that a combination formulation with all ingredients including hydroxypropylmethyl cellulose (HPMC), shows essentially no corneal precipitation in vitro.
  • HPMC hydroxypropylmethyl cellulose
  • Figure 2 shows that a control combination formulation with all ingredients except HPMC leads to corneal precipitation in vitro.
  • Figure 3 shows a generic formulation of CILOXAN® exhibiting considerable reduction in assay values when exposed to radiation over a 24h period. The figure further shows that when exposed to similar radiation over a 24h period, the compositions that are part of these inventions are much more stable by comparison.
  • Figure 4 shows the stability of a combination formulation when exposed to radiation over a 24h period.
  • Figure 5 shows the stability of a combination formulation when exposed to radiation over a 24h period.
  • Subjects to be treated by the methods and compositions of the present invention are, in general, human subjects, but may also include other animal subjects, particularly mammalian subjects such as dogs, cats, horses and rabbits, for veterinary purposes.
  • aqueous pharmaceutical compositions comprising:
  • a fluoroquinolone such as Ciprofloxacin typically included in an amount ranging from 1, 3, 5 or 8 mg/mL to 10, 20, 30, 50, 60 or 100 mg/mL of ciprofloxacin depending upon the intended use;
  • a steroid including corticosteroids and prodrugs thereof
  • a non-steroidal anti-inflammatory compound which when included are present in an amount ranging from 1, 5 or 15 mg/mL up to 30, 60 or 100 mg/mL, depending upon the intended use
  • cyclodextrin including combinations of cyclodextrins, typically included in an amount ranging from 1 to 7, 12 , 15, 25, 30, 40 or 50 % by weight
  • an acid preferably a hydroxy acid, typically included in an amount ranging from 0.1 to 3, 10 or 25 molar equivalents thereof;
  • a water soluble polymer which when included may be included in an amount ranging from about 0.05 to 1.5, 4 or 5 percent by weight of the aqueous formulation;
  • a co-solubilizer such as a surfactant or Vitamin E TPGS, which when present is typicallyincluded in an amount of from 1, 2, or 5% up to 10 or 20 % of the formulation; and (h) water to balance; the formulation preferably having a pH between about 4,
  • Lyophilized compositions which can be reconstituted with water to yield a composition, as described above are also an aspect of the present invention.
  • compositions in solid form comprised of ciprofloxacin, cyclodextrin and an acid as described above, and in the amounts as described above, are also an aspect of this invention.
  • compositions are pharmaceutically acceptable in that they are sterile, pyrogen free, and suitable for topical or parenteral administration to a subject as described herein.
  • Fluoroquinolones that may be used to cany out the present invention include but are not limited to Gatifloxacin, Moxifloxacin, Sitafloxacin, Lomefloxacin, Grepafioxacin, Gemifloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Trovafloxacin, Ciprofloxacin etc..
  • Gatifloxacin Gatifloxacin, Moxifloxacin, Sitafloxacin, Lomefloxacin, Grepafioxacin, Gemifloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Trovafloxacin, Ciprofloxacin etc.
  • Such compounds are known and can be obtained from commercial sources or produced by techniques known in the art (See,
  • Ciprofloxacin (l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-7-(l- piperazinyl) -3- quinolinecarboxylic acid) is known and can be obtained from commercial sources or produced by techniques known in the art (See, e.g., U.S. Patent No. 4,670,444; Mather et al, American Journal of Ophthalmology, Vol. 133, No. 4, p463-466, 2002; P. C. Appelbaum et al, International Journal of Antimicrobial Agents, 16, 2000, p5-15; Tai-Lee Ke et al, Journal of Ocular Pharmacology and Therapeutics, Vol. 17, No. 6, p555-562, 2001; Physicians Desk Reference; Lichenstein, Contemporary Pediatrics, 2002, pl6-19; Ross et al, International Journal of Pharmaceutics, 63 (1990), 237-250).
  • Steroid (or “steroidal") compounds that can be used to carry out the present invention include but are not limited to cortisone, hydrocortisone, corticosterone, deoxycorticosterone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexamethazone, fludrocortisone, combinations thereof, etc., are known and can be obtained from commercial sources.
  • the term "steroids” as used herein includes corticosteroids glucocorticoids, prodrugs of all thereof.
  • Non-steroidal anti-inflammatory drugs that may be used to cany out the present invention include but are not limited to selected from aspirin, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nambumetone, acetaminophen, as well as COX-2 inhibitors such as nimesulide, NS- 398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-58125, etoricoxib, RS-57067, L-748780, L-761066, APHS, etodolac, meloxicam, and S-24
  • cyclodextrins can be used to carry out the present invention, including ⁇ cyclodextrins, ⁇ cyclodextrins, ⁇ cyclodextrins, and ⁇ cyclodextrins (and which cyclodextrins may be in the form of derivatives such as sulfoalkylether cyclodextrins or hydroxyalkyl cyclodextrins).
  • the amount of cyclodextrin will depend in part upon the amount of active ingredient to be included in the composition, but in general will be from about 1 to 7, 12, 30 or 40 percent by weight (for topical or injectable formulations) or from about 1 to 15, 25 or 50 percent by weight (for buccal/oral formulations).
  • Sulfoalkylether cyclodextrins that may be used to carry out the present invention may be of the following formula:
  • n 4, 5, 6 or 7 conesponding ⁇ , ⁇ , ⁇ or ⁇ cyclodextrin
  • Ri through R 9 are independently -O- or a -O-(C 2 through C 6 alkylene)-SO 3 " group, wherein at least one of Ri and R 2 is independently a -O-(C 2 through C 6 alkylene)-SO 3 ⁇ group, preferably a -O-(CH 2 ) m -SO 3 ⁇ group, wherein m is 2 to 6 and Si through S 9 are independently pharmaceutically acceptable cations including H + , alkali metal cations, alkali earth metal cations and organic cations (WO 02/074200). Hydroxyalkyl cyclodextrins used to carry out the present invention may be of the formula:
  • the O- group can be attached to any of the methylene carbons.
  • CH CH(0 " )CH 3 and Si through S 9 are independently pharmaceutically acceptable cations including H 1" .
  • Any suitable hydroxy acid may be used to carry out the present invention, including but not limited to citric acid, ascorbic acid, malic acid, and tartaric acid, gluconic acid, lactic acid, treonic acid, and , ⁇ , ⁇ , ⁇ or higher order aliphatic, alicyclic or aromatic hydroxy acids.
  • the amount of hydroxy acid included will depend in part upon the amount of active ingredient to be included in the composition, but in general will be from about 0.1 up to about 3, 10 or 25 molar equivalents in the aqueous formulation.
  • hydroxy acids are cunently preferred, other acids, including mineral or organic acids such as phosphoric acid, sulfuric acid, hydrochloric acid, acetic acid, etc., may also be used. Any suitable water soluble polymer may be used herein. In one prefened embodiment the polymer has an apparent viscosity of 1 to 100 mPa.s when dissolved in a 2% aqueous solution at 20°C solution.
  • suitable water soluble polymers include, but are not limited to, alkylcelluloses such as methylcellulose, hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose; hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose; carboxyalkylcelluloses such as carboxymethylcellulose; alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose; carboxyalkylalkylcelluloses such as carboxymethylethylcellulose; carboxyalkylcellulose esters; starches; pectins such as sodium carboxymethylamylopectin; chitin derivatives such as chitosan; polysaccharides such as alginic acid, alkali metal and ammonium salts thereof, carrageenans, galactomannans, traganth, agar-agar, gum arabicum, guar gum and x
  • co-solubilizer Any suitable co-solubilizer may also be used to cany out the present invention.
  • co-solubilizers include, but are not limited to, Pluronics (F-68, F-84 and P-103), Polaxamers, Vitamin E TPGS, Tweens (20, 60, 80), aliphatic alcohols and other agents known to those skilled in the art.
  • compositions as described herein may include a tonicity modifier.
  • a tonicity modifier examples include, but are not limited to, NaCl, dextrose, glycerin, mannitol, and potassium chloride.
  • the tonicity of the composition is at least 100, 180 or 270 milli-Osmoles (mOsm), up to about 330, 540 to 600 mOsm, adjusted if desired by the inclusion of a tonicity modifier in the amount necessary to achieve an osmolarity within a range as given above.
  • NaCl is utilized as a tonicity modifier, it may be included in an amount ranging from 0.01, 0.2 or 0.35 percent by weight, up to about 0.55, 3 or 10 percent by weight (with 0.45% by weight NaCl cunently prefened).
  • Compositions as described herein may also contain a preservative.
  • any suitable preservative may be used to carry out the present invention, including but not limited to chlorobutanol, sorbic acid, salts of sorbic acid, EDTA, alcohol, bronopol, chlorhexidine, imidurea and sodium propionate.
  • the amount of preservative is not critical, but will in general be from about 0.001 to about 0.5, 1 or 2% by weight of the aqueous formulation.
  • Preservatives that are oppositely charged, such as B AK are not suggested in formulations comprising of SBECD, also due to potential loss of activity due to complexation.
  • Antimicrobial agents, such as parabens, which are capable of forming inclusion complexes them selves are also not prefened due to competitive displacement of the active.
  • the ability of a molecule to be effectively solubilized by a cyclodextrin depends on variety of factors including the size of the cavity of the cyclodextrin being used, the size of the molecule etc., While some molecules effectively fonn a binary complex (drug-cyclodextrin complex), others might not. hi a binary complex, addition of an appropriate amount of the guest molecule to an aqueous solution of the cyclodextrin at an appropriate concentration, at the appropriate temperature and agitation rate typically leads to the formation of a clear solution of the host-guest complex.
  • the hydrophobic molecule will dissolve in an aqueous solution of the cyclodextrin without the help of a co- solubilizer such as ethanol (J. Pitha et al, International Journal of Pharmaceutics, 80, 1992, p253-258).
  • a co- solubilizer such as ethanol
  • binary complexes are propofol-SBECD (WO 02/074200) and voriconazole-SBECD.
  • an aqueous solution of cyclodextrin is first prepared. To it is dispersed the drug, followed by addition of hydroxy acid. To it are added the water- soluble polymer, preservative, anti-oxidant or any other pharmaceutically acceptable additives.
  • the polymer solution and the CD/drug/hydroxy acid solutions are separately prepared and mixed, followed by the addition of other pharmaceutically acceptable ingredients.
  • Other methods include addition of any and all of the reagents in any combination or permutation possible.
  • Another method includes mixing any or all the ingredients in the solid form before addition to water or any organic solvent.
  • Various process parameters can be manipulated as desired, such as temperature control or modulation, agitation, sonication, autoclaving and pressurization or any other technique known to those skilled in the art.
  • Another method includes preparing the liquid formulation as mentioned above or otherwise, and subsequently isolating the solid material by freeze drying, spray drying, spray- freeze drying, antisolvent precipitation, kneading, process involving supercritical fluid or near super critical fluid or any other methods for making a solid or liquid dosage form known to those skilled in the art. Note that, in order for one to achieve the therapeutic concentration of 3 mg/mL, ciprofloxacin should be solubilized 37.5 fold.
  • solubilization has to be even higher (75 fold for a 6 mg/mL solution and 112.5 fold for a 9 mg/mL solution).
  • Attempts at solubilization using 4.5 % solution of SBECD led to an increase in ciprofloxacin solubility to 160 ⁇ g/mL. This conesponds to a twofold increase in solubility and is far short of the 37.5 fold improvement that is desired.
  • the amount of CD in a solution formulation should be kept to a minimum (Thorsteinn Loftsson et al, Advanced Drug Delivery Reviews, 36 (1999), p59-79; Thorsteinn Loftsson et al, International Journal of Pharmaceutics, 225, 2001, pl5-30).
  • the amount of citric acid required to effect the required solubilization is also an aspect of this invention. If one has to use to enough citric acid such that the pH of the invention is same or less than the commercial formulation of 4.5, the utility of the invention will be somewhat reduced. Equivalence determination studies demonstrated that this was not the case. For effective solubilization one needs to use only a minimum of 0.5 mole equivalents of citric acid for every mole equivalents of ciprofloxacin or other fluoroquinolone. Accordingly in this invention, the pH of a 6 mg/mL formulation (doubly potent) is at about pH 5.0. This is about 0.5 units higher than the commercial formulation which is only half potent. The clinical benefits of this invention are readily apparent.
  • Corneal precipitation has been reported as an undesirable side effect to patients using CILOXAN® ciprofloxacin formulations for conjunctivitis and especially for corneal ulcers (H. M. Liebowitz, American Journal of Ophthalmology, 1991, 112, 34S-47; D. J. Parks et al, American Journal of Ophthalmology, 1993, 115, 471-477; R. A. Eiferman, Journal of Cataract and Refractive Surgery, 2001, 27, pi 701-1702; H. N. Madhavan, Cornea, 1999, 18:549-552).
  • a water soluble polymer such as described above to reduce, minimize, control prevent corneal precipitation of the drug at pH's higher than the pKa of the drug.
  • the prefened polymers are MC, CMC, HPMC, PVP, PVA and poloxamers.
  • the most prefened polymers are HPMC and PVA.
  • aqueous based combination formulations of fluoroquinolones and anti-inflammatory agents, such as steroids, corticosteroids or non-steroidal agents are included.
  • fluoroquinolones and anti-inflammatory agents such as steroids, corticosteroids or non-steroidal agents.
  • anti-inflammatory agents such as steroids, corticosteroids or non-steroidal agents.
  • Such formulations are not reported in literature or available commercially. Due to the sparse water solubility of fluoroquinolones and steroids, manufacture of an aqueous solution of these drugs is not feasible.
  • This invention provides for a way of manufacturing a true aqueous based solution of these two drags.
  • the formulations shall be of higher potency and with pH's between 5 and 7.
  • compositions of the present invention can be used to treat subjects as described herein in a manner analogous to that utilized with present fluoroquinolone compositions.
  • Topical compositions may be administered to the eye of a subject as droplets as desired to treat eye infections.
  • Oral or injectable formulations may be likewise administered in accordance with known techniques.
  • Bacterial infections of the eye and/or inflammations which may be treated by the topical or ophthalmic methods and compositions described herein include but are not limited to infections with gram-Positive bacteria such as Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Viridans Group), as well as infections with gram-negative bacteria such as Haemophilus influenzae, Pseudomonas aeruginosa, and Serratia marcescens.
  • gram-Positive bacteria such as Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Viridans Group), as well as infections with gram-negative bacteria such as Haemophilus influenzae, Pse
  • bacterial infections including but not limited to bacterial infections of the skin, joints, and airways, which may be treated with the intravenous methods and compositions described herein include infections with aerobic gram- positive microorganisms such as Enterococcus faecalis, Staphylococcus aureus (methicillin-susceptible strains only), Staphylococcus epidermidis (methicillin- susceptible strains only) , Staphylococcus saprophyticus, Streptococcus pneumoniae (penicillin-susceptible strains), and Streptococcus pyogenes, and infections with Aerobic gram-negative microorganisms such as Citrobacter diversus Morganella morganii, Citrobacter freundii Proteus mirabilis, Enterobacter cloacae Proteus vulgaris, Escherichia coli Providencia rettgeri, Haemophilus influenzae Providencia stuartii, Haemophilus parainflu
  • CD means cyclodextrin
  • SBE7- ⁇ -CD means sulfobutylether7- ⁇ - cyclodextrin
  • HPCD 2-hydroxypropylether- ⁇ -cyclodextrin
  • HPMC means hydroxypropylmethyl cellulose
  • PVA means polyvinyl alcohol
  • Tonicity modifiers such as sodium chloride are added, if needed.
  • the solution was brought up to volume or weight with distilled water under agitation.
  • Preservative chlorobutanol
  • concentration 0.1% to 1%.
  • the solution was brought up to volume or weight with distilled water under agitation.
  • Tonicity modifiers such as sodium chloride are added, if needed. This solution was filtered through a filter of 0.45 ⁇ m or lower porosity and freeze-dried.
  • EXAMPLE 5 Appropriate amounts of SBE7- ⁇ -CD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stined, ciprofloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stined until it became clear.
  • Ciprofloxacin HPLC Method This example describes methods for the analysis of ciprofloxacin content in compositions of the invention by high performance liquid chromatography (HPLC).
  • Ciprofloxacin standard 0.05 mg/mL at 5.0, 7.5, 10, 12.5 and 15.0 ⁇ L volumes, which corresponded to 0.25, 0.375, 0.5, 0.625, and 0.75 ⁇ g of
  • Ciprofloxacin loaded onto the column were all ⁇ 1.3%.
  • Ciprofloxacin by exposing a solution of the active to 2 M methanolic acid (HC1 in methanol) and 0.2 M NaOH in water under ambient and heated conditions. Combine 1.0 mg/mL of Ciprofloxacin with 2 M methanolic acid and also combine 1.0 mg/mL of Ciprofloxacin with 0.2 M NaOH in water to get a final concentration of 0.5 mg/mL Ciprofloxacin. Store solutions at ambient conditions and at 80 °C for approximately 24 hours. Control samples were also prepared by diluting 1.0 mg/mL of Ciprofloxacin with the appropriate amount of solvent (either methanol or water) and will also be stored under ambient and heated conditions. Method: Same as assay method. Results: Under the conditions of heating with or without base or acid, new peaks were detected at the following relative retention times (RRT's, relative to the main ciprofloxacin peak). 0.27, 0.36, 0.55, 0.60, 0.68 and 0.72.
  • RRT's relative retention times
  • Preservative chlorobutanol
  • concentration is between 0.1% to 1%.
  • the solution was brought up to volume or weight with distilled water under agitation.
  • Tonicity modifiers such as sodium chloride are added, if needed.
  • This solution was filtered through a filter of 0.45 ⁇ m or lower porosity and further processed to obtain a solid or liquid formulation.
  • HPCD and SBE7- ⁇ -CD were dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stined, Gatifloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of Gatifloxacin). The solution was stined until it became clear.
  • water soluble polymer hydroxypropylmethyl cellulose (viscosities ranging from 2 cps to 40, 000 cps)
  • concentration of the polymer is about 0.1% to 10%
  • Preservative, chlorobutanol was added such that its concentration is between 0.1 % to 1%>.
  • Tonicity modifiers such as sodium chloride are added, if needed.
  • the solution was brought up to volume or weight with distilled water under agitation. This solution was filtered through a filter of 0.45 ⁇ m or lower porosity and further processed to obtain a liquid or solid formulation.
  • a 0.1005mg/mL Standard Solution had a response of 0.34AU. There was 0.1 %RSD between ten injections.
  • %RSD ⁇ o of each set of injections were all ⁇ 0.2%.
  • Ciprofloxacin Performed 6 injections of Ciprofloxacin ranging from 0.00002367 to 0.0007575 mg/mL in the attempt to get an estimation of LOD/LOQ.
  • the prevention of corneal precipitation with a soluble polymer such as HPMC is a further object of the present invention.
  • a soluble polymer such as HPMC
  • HPMC pH's higher than the pKa of fluoroquinolones, HPMC, and to a very slightly reduced degree PVA, is able to prevent corneal precipitation even at high concentrations, in vitro. These concentrations are far higher than the solubility of fluoroquinolones in solutions of HPMC and PVA at concentrations in the formulations..
  • This result is particularly unexpected since various published reports have stated that in order for a water soluble polymer to co-solubilize a hydrophobic drug in the presence of a cyclodextrin, micelle formation is necessary (A. M.
  • Figure 1 shows that a combination formulation (Ciprofloxacin/ Hydrocortisone, 0.6%/0.6%) with all ingredients including HPMC, shows essentially no corneal precipitation in vitro. This is infened from the fact that the total and soluble concentrations are same, as the pH of the tear film gets adjusted to normal lachrymal pH as a function of time, within experimental enor. While this in vitro tear turn-over study simulated first-order nasolachrymal drainage and equilibration to lachrymal pH as a function of time, it does not simulate other important parameters such as increase in residence time in the eye as the viscosity of the formulation is increased and induced lachrymation as a function of the formulation.
  • Figure 2 shows that a control combination formulation
  • Figure 3 shows that CILOXAN® (0.3% Ciprofloxacin Hydrochloride) when exposed to a photostability chamber (ICH conditions), undergoes substantial degradation over a 24 hr period.
  • the figure also shows that 0.3%» ciprofloxacin formulation composed according to the inventions given above are considerably more stable than CILOXAN® itself.
  • Figure 4 shows that CILOXAN® (0.3% Ciprofloxacin Hydrochloride) when exposed to a photostability chamber (ICH conditions), undergoes substantial degradation over a 24 hr period.
  • the figure also shows that a triply potent ciprofloxacin formulation composed according to the inventions is considerably more stable than than CILOXAN® itself.
  • Figure 5 shows the photo stability of ciprofloxacin and gatifloxacin in ciprofloxacin/hydrocortisone and gatifloxacin/hydrocortisone combination formulations respectively.
  • Figure 6 shows that formulations that are part of these inventions are stable on long-term storage even under accelerated stability conditions. No precipitation of the active was observed throughout.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

A pharmaceutical composition comprising a fluoroquinolone such as ciprofloxacin, cyclodextrin, and a hydroxy acid is described. The composition may be an aqueous composition, with such aqueous compositions preferably having a pH between 5 and 7. In some preferred embodiments, the composition further comprises a soluble polymer.

Description

A FLUOROQUINOLONE AQUEOUS FORMULATION OF A PH BETWEEN 4 AND 7 COMPRISING I . A . CYCLODEXTRIN , HYDROXYACID
FIELD OF INVENTION The present invention relates to liquid formulations, in particular pharmaceutical formulations, containing fluoroquinolone antibacterial agents such as ciprofloxacin, and methods of making the same.
BACKGROUND OF THE INVENTION Ciprofloxacin (l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-7-(l- piperazinyl) -3- quinolinecarboxylic acid) is a fluoroquinolone widely used in the treatment of bacterial infections (Rookaya Mather et al, American Journal of Ophthalmology, Vol. 133, No. 4, p463-466, 2002; P. C. Appelbaum et al, International Journal of Antimicrobial Agents, 16, 2000, p5-15). Fluoroquinolone antibacterial agents such as ciprofloxacin agents are preferred due to, among other reasons, their low MIC9o's compared with conventional antibiotics and slower formation of resistant bacterial strains against them. For example, the MIC90 of ciprofloxacin is generally around 0.5 μg/g whereas the MIC 0 of gentamicin is 10 μg/gm (Tai-Lee Ke et al, Journal of Ocular Pharmacology and Therapeutics, Vol. 17, No. 6, p555-562, 2001). Ciprofloxacin is widely used in treatment of bacterial conjunctivitis of the eye and for treatment of corneal ulcers (Physicians Desk Reference; Steven J. Lichenstein, Contemporary Pediatrics, 2002, pl6-19). The chemical structure of ciprofloxacin is:
Figure imgf000002_0001
Ciprofloxacin is soluble in dilute (0.1N) hydrochloric acid and is practically insoluble in water and ethanol. The aqueous solubility of ciprofloxacin is 79 μg/mL (Danna L. Ross et al, International Journal of Pharmaceutics, 63 (1990), 237-250). In order to achieve the 0.3% (3 mg/mL) concentration of ciprofloxacin necessary for therapeutic use in the currently marketed ciprofloxacin formulation of CILOXAN®, an acidic buffer is employed at pH 4.5. Upon administration of CILOXAN® ciprofloxacin formulation to the eye, frequent burning and stinging sensation has been clinically reported (Physicians Desk Reference). This is due to the acidic fonnulation pH of 4.5 and due to the invasive nature of the preservative, benzalkonium chloride (BAK), used in the formulation of CILOXAN®. Also, the acidic pH of 4.5 leads to induced lachrymation, which in turn increases the drainage of the drug via the nasolachrymal duct (V. H. L. Lee et al, Journal of Ocular Pharmacology, 2 (1986), p67-108; Thorsteinn Loftsson et al, Advanced Drug Delivery Reviews, 36 (1999), p59-79; Marco Fabrizio Saettone, Pharmatech, 2002, pi -6). Such increased drainage is largely responsible for decreased availability of the therapeutic agent to the eye. This necessitates frequent and prolonged administration of the drug to eliminate the pathogens in question. It is therefore desirable to have a ciprofloxacin formulation which is formulated at a higher pH and which does not have the detrimental effects of the antimicrobial preservative currently being used.
Higher potency formulations of ciprofloxacin would be clinically desirable because they should increase the effective concentration of the drug that is locally delivered to the eye, which in turn will decrease the dosing regimen, increase patient compliance and decrease the duration of therapy (Steven J. Lichenstein, Contemporary Pediatrics, 2002, pl6-19). Current teclmiques do not provide a feasible way to produce such higher potency formulations because further reductions in pH would lead to even more serious side effects. It is therefore desirable to have a ciprofloxacin drug formulation of higher potency (greater than 0.3%) and preferably formulated at a higher pH (higher than 4.5). Formation of fluoroquinolone resistant strains of bacteria has been reported (Thomas J. Dougherty et al, DDT, Vol. 6, No. 10, 2001, p529-536). It is believed that this phenomenon is due to the decreased concentration of the therapeutic agent, concentrations below MIC90 (minimum inhibitory concentration), in the presence of pathogens. "To avoid the development of resistance to topical antibiotics, high concentrations of a bactericidal drug with good solubility should be used at a dosing frequency that ensures that the drug concentrations are maintained above the MIC90 of the suspected pathogens" (Steven J. Lichenstein, Contemporary Pediatrics, 2002, pi 6- 19). It is therefore desirable to have formulations of higher potency (greater than 0.3%) that will maintain concentrations of the drug higher than MIC90 in the eye. Such a formulation should increase therapeutic efficiency, decrease the likelihood of formation of resistant strains of bacteria, decrease the duration of therapy and decrease the dosing regimen. Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for pharmaceutical administration has been disclosed by Stella et al. in US patent 5,134,127 ('127 patent). Particular examples are sulfoalkylether cyclodextrins combined with various drugs, as 'host- guest' complexes. Exemplification has been achieved by the use of sulfoalkylether cyclodextrins in combination with digoxin, progesterone and testosterone. Among other things, this patent requires that the inclusion (clathrate complex) be formed prior to formulation. US patent 5,376,645 ('645 patent) also by Stella et al is a continuation of the '127 patent. In addition to the exemplifications in the '127 patent, further examples in the '645 patent are phenytoin and naproxen. US Patent No. 5,874,418 ('418 patent) and its continuation, US
Patent No. 6,046,177, both by Stella et al., disclose the use of sulfoalkylether cyclodextrin based solid pharmaceutical formulations and their use. The composition comprises of a physical mixture of a sulfoalkylether cyclodextrin with a therapeutic agent, a major portion of which is not complexed to the cyclodextrin. US Patent No. 5,324,718 and its continuation, US Patent No.
5,472,954, both by Thorsteimi Loftsson, provide a method for enhancing the complexation of a cyclodextrin with a lipophilic drug. The use of a water-soluble polymer such as HPMC as a co-solubilizer along with a cyclodextrin is disclosed. It one embodiment the polymer and the cyclodextrin are dissolved in the aqueous medium before the lipophilic drug is added and that solution be maintained from 30 °C to 150 °C for specified periods of time.
US Patent No. 5,855,916 to Chiesi describes the formation of soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin demonstrating enhanced water solubility. Exemplifications in the '916 patent include terfenadine, cinnarizine, domperidone, astemizole, ketoconazole, tamoxifene, clomifene and itraconazole as base type drugs.
PCT Application WO02/39993 describes a clear solution or gel preparation of a combination drug comprising an anti-inflammatory agent such as a corticosteroid, an anti-infective agent such as a fluoroquinolone a complexation- enhancing polymer, and a solubilizer exhibiting an inclusion phenomenon.
SUMMARY OF THE INVENTION A first aspect of the present invention is an aqueous pharmaceutical composition comprising or consisting essentially of a fluoroquinolone active agent such as ciprofloxacin, cyclodextrin, a hydroxy acid, and water, the composition preferably having a pH between 4 and 7.
In some preferred embodiments, the composition further comprises or consists essentially of a soluble polymer.
In some embodiments, the composition further includes a steroidal or non-steroidal anti-inflammatory agent.
In some embodiments, the composition further comprises or consists essentially of another co-solubilizer such as a vitamin E derivative, detergents such as Tweens or pluronics, etc.
Compositions of the present invention are useful, among other things, for topical applications (e.g., to the eye, ear/ear passages, nose/nasal passages, etc.) and injectable applications (e.g., for subcutaneous, intramuscular, or intraperitoneal injection, etc.). A second aspect of the present invention is a method of treating a bacterial infection and/or inflammation of an eye of a subject in need thereof, comprising topically administering a formulation as described above to the eye of the subject in an amount effective to treat the bacterial infection and/or inflammation.
A further aspect of the present invention is a method of treating a bacterial infection and/or inflammation of a topical surface of a subject such as an ear, nose or other skin surface need thereof, comprising topically administering a formulation as described above to the eye of the topical surface of subject in an amount effective to treat the bacterial infection and/or inflammation.
A further aspect of the present invention is an improved method of topically applying a pharmaceutical composition containing an active compound such as ciprofloxacin or other fluoroquinolone active agent to the eye of a subject in need thereof, which active compound precipitates from said composition on the eye, such as on the cornea, of the subject, the improvement comprising including a soluble polymer in said composition in an amount effective to reduce the precipitation of the active compound on the cornea of the subject.
A still further aspect of the present invention is an improved topical pharmaceutical composition containing an active compound (such as ciprofloxacin or other fluoroquinolone) used to topically apply said active compound to the eye of a subject in need thereof, which active compound precipitates from the composition on the eye or cornea of the subject, the improvement comprising including from 0.05 to 5% by weight of a soluble polymer in the composition to reduce the precipitation of the active compound on the eye or cornea of the subject.
The foregoing and other objects and aspects of the present invention are explained in detail in the drawings herein and the specification set forth below.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows that a combination formulation with all ingredients including hydroxypropylmethyl cellulose (HPMC), shows essentially no corneal precipitation in vitro.
Figure 2 shows that a control combination formulation with all ingredients except HPMC leads to corneal precipitation in vitro.
Figure 3 shows a generic formulation of CILOXAN® exhibiting considerable reduction in assay values when exposed to radiation over a 24h period. The figure further shows that when exposed to similar radiation over a 24h period, the compositions that are part of these inventions are much more stable by comparison.
Figure 4 shows the stability of a combination formulation when exposed to radiation over a 24h period.
Figure 5 shows the stability of a combination formulation when exposed to radiation over a 24h period.
Figure 6 shows that formulations that are part of these inventions are stable on long-term storage even under accelerated stability conditions. No precipitation of the active was observed throughout. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Subjects to be treated by the methods and compositions of the present invention are, in general, human subjects, but may also include other animal subjects, particularly mammalian subjects such as dogs, cats, horses and rabbits, for veterinary purposes.
As noted above, the present invention provides aqueous pharmaceutical compositions comprising:
(a) A fluoroquinolone such as Ciprofloxacin, typically included in an amount ranging from 1, 3, 5 or 8 mg/mL to 10, 20, 30, 50, 60 or 100 mg/mL of ciprofloxacin depending upon the intended use;
(b) optionally, but in some embodiments preferably, a steroid (including corticosteroids and prodrugs thereof) or a non-steroidal anti-inflammatory compound, which when included are present in an amount ranging from 1, 5 or 15 mg/mL up to 30, 60 or 100 mg/mL, depending upon the intended use; (c) cyclodextrin (including combinations of cyclodextrins), typically included in an amount ranging from 1 to 7, 12 , 15, 25, 30, 40 or 50 % by weight;
(d) an acid, preferably a hydroxy acid, typically included in an amount ranging from 0.1 to 3, 10 or 25 molar equivalents thereof;
(e) optionally, but in some embodiments preferably, a water soluble polymer, which when included may be included in an amount ranging from about 0.05 to 1.5, 4 or 5 percent by weight of the aqueous formulation;
(f) optionally a co-solubilizer such as a surfactant or Vitamin E TPGS, which when present is typicallyincluded in an amount of from 1, 2, or 5% up to 10 or 20 % of the formulation; and (h) water to balance; the formulation preferably having a pH between about 4,
4.5 or 5, up to about 7.
Lyophilized compositions, which can be reconstituted with water to yield a composition, as described above are also an aspect of the present invention.
Compositions in solid form comprised of ciprofloxacin, cyclodextrin and an acid as described above, and in the amounts as described above, are also an aspect of this invention.
The compositions are pharmaceutically acceptable in that they are sterile, pyrogen free, and suitable for topical or parenteral administration to a subject as described herein. Fluoroquinolones that may be used to cany out the present invention include but are not limited to Gatifloxacin, Moxifloxacin, Sitafloxacin, Lomefloxacin, Grepafioxacin, Gemifloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Trovafloxacin, Ciprofloxacin etc.. Such compounds are known and can be obtained from commercial sources or produced by techniques known in the art (See, e.g., U.S. Patent No. 4,670,444; Mather et al, American Journal of Ophthalmology, Vol. 133, No. 4, p463-466, 2002; P. C. Appelbaum et al, International Journal of Antimicrobial Agents, 16, 2000, p5-15; Tai-Lee Ke et al, Journal of Ocular Pharmacology and Therapeutics, Vol. 17, No. 6, p555-562, 2001; Physicans Desk Reference; Lichenstein, Contemporary Pediatrics, 2002, pl6-19; Ross et al, International Journal of Pharmaceutics, 63 (1990), 237-250).
Ciprofloxacin (l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-7-(l- piperazinyl) -3- quinolinecarboxylic acid) is known and can be obtained from commercial sources or produced by techniques known in the art (See, e.g., U.S. Patent No. 4,670,444; Mather et al, American Journal of Ophthalmology, Vol. 133, No. 4, p463-466, 2002; P. C. Appelbaum et al, International Journal of Antimicrobial Agents, 16, 2000, p5-15; Tai-Lee Ke et al, Journal of Ocular Pharmacology and Therapeutics, Vol. 17, No. 6, p555-562, 2001; Physicians Desk Reference; Lichenstein, Contemporary Pediatrics, 2002, pl6-19; Ross et al, International Journal of Pharmaceutics, 63 (1990), 237-250).
Steroid (or "steroidal") compounds that can be used to carry out the present invention include but are not limited to cortisone, hydrocortisone, corticosterone, deoxycorticosterone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexamethazone, fludrocortisone, combinations thereof, etc., are known and can be obtained from commercial sources. The term "steroids" as used herein includes corticosteroids glucocorticoids, prodrugs of all thereof.
Non-steroidal anti-inflammatory drugs that may be used to cany out the present invention include but are not limited to selected from aspirin, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nambumetone, acetaminophen, as well as COX-2 inhibitors such as nimesulide, NS- 398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-58125, etoricoxib, RS-57067, L-748780, L-761066, APHS, etodolac, meloxicam, and S-2474, and mixtures thereof.
Any suitable cyclodextrin can be used to carry out the present invention, including α cyclodextrins, β cyclodextrins, γ cyclodextrins, and δ cyclodextrins (and which cyclodextrins may be in the form of derivatives such as sulfoalkylether cyclodextrins or hydroxyalkyl cyclodextrins). The amount of cyclodextrin will depend in part upon the amount of active ingredient to be included in the composition, but in general will be from about 1 to 7, 12, 30 or 40 percent by weight (for topical or injectable formulations) or from about 1 to 15, 25 or 50 percent by weight (for buccal/oral formulations).
Sulfoalkylether cyclodextrins that may be used to carry out the present invention may be of the following formula:
Figure imgf000009_0001
where: n is 4, 5, 6 or 7 conesponding α, β, γ or δ cyclodextrin
Ri through R9 are independently -O- or a -O-(C2 through C6 alkylene)-SO3 " group, wherein at least one of Ri and R2 is independently a -O-(C2 through C6 alkylene)-SO3 ~ group, preferably a -O-(CH2)m-SO3 ~ group, wherein m is 2 to 6 and Si through S9 are independently pharmaceutically acceptable cations including H+, alkali metal cations, alkali earth metal cations and organic cations (WO 02/074200). Hydroxyalkyl cyclodextrins used to carry out the present invention may be of the formula:
Figure imgf000010_0001
where: n is 4, 5, 6 or 7 conesponding α, β, γ or δ cyclodextrin Ri through R are independently -O- or a -O-(C2 through C6 alkylene)- O" group, wherein at least one of Rt and R2 is independently a -O-(C2 through C6 alkylene) O" group, preferably a -0-(CH )m O" group, wherein m is 2 to 6. The O- group can be attached to any of the methylene carbons. For eg: CH CH(0")CH3 and Si through S9 are independently pharmaceutically acceptable cations including H1". Any suitable hydroxy acid may be used to carry out the present invention, including but not limited to citric acid, ascorbic acid, malic acid, and tartaric acid, gluconic acid, lactic acid, treonic acid, and , β, γ, δ or higher order aliphatic, alicyclic or aromatic hydroxy acids. The amount of hydroxy acid included will depend in part upon the amount of active ingredient to be included in the composition, but in general will be from about 0.1 up to about 3, 10 or 25 molar equivalents in the aqueous formulation.
While hydroxy acids are cunently preferred, other acids, including mineral or organic acids such as phosphoric acid, sulfuric acid, hydrochloric acid, acetic acid, etc., may also be used. Any suitable water soluble polymer may be used herein. In one prefened embodiment the polymer has an apparent viscosity of 1 to 100 mPa.s when dissolved in a 2% aqueous solution at 20°C solution. Examples of suitable water soluble polymers include, but are not limited to, alkylcelluloses such as methylcellulose, hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose; hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose; carboxyalkylcelluloses such as carboxymethylcellulose; alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose; carboxyalkylalkylcelluloses such as carboxymethylethylcellulose; carboxyalkylcellulose esters; starches; pectins such as sodium carboxymethylamylopectin; chitin derivatives such as chitosan; polysaccharides such as alginic acid, alkali metal and ammonium salts thereof, carrageenans, galactomannans, traganth, agar-agar, gum arabicum, guar gum and xanthan gum; polyacrylic acids and salts thereof; polymethacrylic acids and salts thereof, including methacrylate copolymers polyvinylpynolidone, copolymers of polyvinylpyrrolidone with vinyl acetate; polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide; etc. Currently preferred is hydroxypropylmethylcellulose, manufactured by Dow Chemical Industries, USA and also by Shin-Etsu Chemical Company, Japan.
Any suitable co-solubilizer may also be used to cany out the present invention. Such co-solubilizers include, but are not limited to, Pluronics (F-68, F-84 and P-103), Polaxamers, Vitamin E TPGS, Tweens (20, 60, 80), aliphatic alcohols and other agents known to those skilled in the art.
Compositions as described herein may include a tonicity modifier. Examples include, but are not limited to, NaCl, dextrose, glycerin, mannitol, and potassium chloride. In general, the tonicity of the composition is at least 100, 180 or 270 milli-Osmoles (mOsm), up to about 330, 540 to 600 mOsm, adjusted if desired by the inclusion of a tonicity modifier in the amount necessary to achieve an osmolarity within a range as given above. For example, where NaCl is utilized as a tonicity modifier, it may be included in an amount ranging from 0.01, 0.2 or 0.35 percent by weight, up to about 0.55, 3 or 10 percent by weight (with 0.45% by weight NaCl cunently prefened). Compositions as described herein may also contain a preservative.
Any suitable preservative may be used to carry out the present invention, including but not limited to chlorobutanol, sorbic acid, salts of sorbic acid, EDTA, alcohol, bronopol, chlorhexidine, imidurea and sodium propionate. The amount of preservative is not critical, but will in general be from about 0.001 to about 0.5, 1 or 2% by weight of the aqueous formulation. Preservatives that are oppositely charged, such as B AK, are not suggested in formulations comprising of SBECD, also due to potential loss of activity due to complexation. Antimicrobial agents, such as parabens, which are capable of forming inclusion complexes them selves are also not prefened due to competitive displacement of the active. As noted above, the ability of a molecule to be effectively solubilized by a cyclodextrin depends on variety of factors including the size of the cavity of the cyclodextrin being used, the size of the molecule etc., While some molecules effectively fonn a binary complex (drug-cyclodextrin complex), others might not. hi a binary complex, addition of an appropriate amount of the guest molecule to an aqueous solution of the cyclodextrin at an appropriate concentration, at the appropriate temperature and agitation rate typically leads to the formation of a clear solution of the host-guest complex. In other words, the hydrophobic molecule will dissolve in an aqueous solution of the cyclodextrin without the help of a co- solubilizer such as ethanol (J. Pitha et al, International Journal of Pharmaceutics, 80, 1992, p253-258). Examples of such binary complexes are propofol-SBECD (WO 02/074200) and voriconazole-SBECD.
Methods of making. In one method of making formulations as described herein an aqueous solution of cyclodextrin is first prepared. To it is dispersed the drug, followed by addition of hydroxy acid. To it are added the water- soluble polymer, preservative, anti-oxidant or any other pharmaceutically acceptable additives. In another method, the polymer solution and the CD/drug/hydroxy acid solutions are separately prepared and mixed, followed by the addition of other pharmaceutically acceptable ingredients. Other methods include addition of any and all of the reagents in any combination or permutation possible. Another method includes mixing any or all the ingredients in the solid form before addition to water or any organic solvent. Various process parameters can be manipulated as desired, such as temperature control or modulation, agitation, sonication, autoclaving and pressurization or any other technique known to those skilled in the art. Another method includes preparing the liquid formulation as mentioned above or otherwise, and subsequently isolating the solid material by freeze drying, spray drying, spray- freeze drying, antisolvent precipitation, kneading, process involving supercritical fluid or near super critical fluid or any other methods for making a solid or liquid dosage form known to those skilled in the art. Note that, in order for one to achieve the therapeutic concentration of 3 mg/mL, ciprofloxacin should be solubilized 37.5 fold. For higher potencies the solubilization has to be even higher (75 fold for a 6 mg/mL solution and 112.5 fold for a 9 mg/mL solution). Attempts at solubilization using 4.5 % solution of SBECD led to an increase in ciprofloxacin solubility to 160 μg/mL. This conesponds to a twofold increase in solubility and is far short of the 37.5 fold improvement that is desired. There are various reasons why the amount of CD in a solution formulation should be kept to a minimum (Thorsteinn Loftsson et al, Advanced Drug Delivery Reviews, 36 (1999), p59-79; Thorsteinn Loftsson et al, International Journal of Pharmaceutics, 225, 2001, pl5-30). Achievement of the desired 3 mg/mL concentration is highly unlikely by simply increasing the percentage of SBECD (levels of pharmaceutical utility) in solution. In other words, formation of a binary complex of ciprofloxacin and SBECD to achieve the necessary solubilization is not feasible. Similar experiments with various concentrations of HPCD also proved that binary complex formation to achieve the desired solubility was not feasible.
However, in the presence of hydroxy acids, such as 0.2% of citric acid, ciprofloxacin complexed effectively with a 4% solution of SBECD. The solubilization achieved was over 112 fold in this particular case. Thus, one can effectively use a hydroxy acid, such as citric, ascorbic, malic, tartaric etc., as a co- solubilizer to achieve an increase in ciprofloxacin or other fluoroquinolone solubility. Such an increase is in a prefened embodiment is synergistic and cannot be achieved by simple binary complexation. Such multicomponent complexes involving ciprofloxacin/SBECD/citric acid have not been reported in literature. One should note that solubility of ciprofloxacin in 0.2% citric acid solution alone is far less (< 3 mg ) than what is achieved by synergistic multicomponent complexation. Similar synergistic complexation is also clearly evident in formulations comprising of Gatifloxacin. For higher potency formulations of Gatifloxacin (0.6%, 0.9%) or higher) synergistic multicomponent formulations are extremely critical since it allows the achievement of higher concentrations without reduction in pH compared to the commercial formulation (Zymar, 0.3%> Gatifloxacin, pH = ca. 6).
The amount of citric acid required to effect the required solubilization is also an aspect of this invention. If one has to use to enough citric acid such that the pH of the invention is same or less than the commercial formulation of 4.5, the utility of the invention will be somewhat reduced. Equivalence determination studies demonstrated that this was not the case. For effective solubilization one needs to use only a minimum of 0.5 mole equivalents of citric acid for every mole equivalents of ciprofloxacin or other fluoroquinolone. Accordingly in this invention, the pH of a 6 mg/mL formulation (doubly potent) is at about pH 5.0. This is about 0.5 units higher than the commercial formulation which is only half potent. The clinical benefits of this invention are readily apparent.
Reduction of corneal precipitation. Corneal precipitation has been reported as an undesirable side effect to patients using CILOXAN® ciprofloxacin formulations for conjunctivitis and especially for corneal ulcers (H. M. Liebowitz, American Journal of Ophthalmology, 1991, 112, 34S-47; D. J. Parks et al, American Journal of Ophthalmology, 1993, 115, 471-477; R. A. Eiferman, Journal of Cataract and Refractive Surgery, 2001, 27, pi 701-1702; H. N. Madhavan, Cornea, 1999, 18:549-552). As has been alluded to before, this phenomenon occurs when the pH of the eye is higher than the pKa of ciprofloxacin (pKa = 6.09, typically around 6 minutes for a true solution formulation) and there is sufficient concentration of the drug still left in the eye. Avoidance of such precipitates is all the more important in these inventions since these inventions are at least as potent as the commercial formulation (3 mg/mL) and prefened formulations are doubly or triply potent or greater compared to the commercial formulation. Corneal precipitations can be observed in vitro using the in vitro tear turn-over model. The fact that the commercial CILOXAN® ciprofloxacin formulation does indeed lead to corneal precipitation has been independently demonstrated by Allergan Inc (B. A. Firestone et al, International Journal of Pharmaceutics, 164 (1998), p 119- 128). These data are confirmed herein.
Thus, in yet another embodiment of this invention, the use of a water soluble polymer such as described above to reduce, minimize, control prevent corneal precipitation of the drug at pH's higher than the pKa of the drug. The prefened polymers are MC, CMC, HPMC, PVP, PVA and poloxamers. The most prefened polymers are HPMC and PVA.
In another embodiment of this invention, aqueous based combination formulations, of fluoroquinolones and anti-inflammatory agents, such as steroids, corticosteroids or non-steroidal agents are included. Such formulations are not reported in literature or available commercially. Due to the sparse water solubility of fluoroquinolones and steroids, manufacture of an aqueous solution of these drugs is not feasible. This invention provides for a way of manufacturing a true aqueous based solution of these two drags. The formulations shall be of higher potency and with pH's between 5 and 7.
Compositions of the present invention can be used to treat subjects as described herein in a manner analogous to that utilized with present fluoroquinolone compositions. Topical compositions may be administered to the eye of a subject as droplets as desired to treat eye infections. Oral or injectable formulations may be likewise administered in accordance with known techniques. Bacterial infections of the eye and/or inflammations which may be treated by the topical or ophthalmic methods and compositions described herein include but are not limited to infections with gram-Positive bacteria such as Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Viridans Group), as well as infections with gram-negative bacteria such as Haemophilus influenzae, Pseudomonas aeruginosa, and Serratia marcescens.
Other bacterial infections, including but not limited to bacterial infections of the skin, joints, and airways, which may be treated with the intravenous methods and compositions described herein include infections with aerobic gram- positive microorganisms such as Enterococcus faecalis, Staphylococcus aureus (methicillin-susceptible strains only), Staphylococcus epidermidis (methicillin- susceptible strains only) , Staphylococcus saprophyticus, Streptococcus pneumoniae (penicillin-susceptible strains), and Streptococcus pyogenes, and infections with Aerobic gram-negative microorganisms such as Citrobacter diversus Morganella morganii, Citrobacter freundii Proteus mirabilis, Enterobacter cloacae Proteus vulgaris, Escherichia coli Providencia rettgeri, Haemophilus influenzae Providencia stuartii, Haemophilus parainfluenzae Pseudomonas aeruginosa, Klebsiella pneumoniae Serratia marcescens, Moraxella catarrhalis, Burkolderia picketti, and inhalation anthrax. The present invention is explained in greater detail in the Examples below, where "CD" means cyclodextrin; "SBE7-β-CD" means sulfobutylether7-β- cyclodextrin; "HPCD" means 2-hydroxypropylether-β-cyclodextrin; "HPMC" means hydroxypropylmethyl cellulose; "PVA" means polyvinyl alcohol.
EXAMPLE 1
Formulation of Ciprofloxacin and Sulfoalkylether Cyclodextrin
The following formulation was made according to the following procedure. SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 2%>. Wliile the aqueous CD solution was being stirred, ciprofloxacin, in amounts that would eventually provide a 3 mg/mL solution, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stirred until it became clear. No viscosity enhancing agents, preservatives or other pharmaceutically acceptable ingredients were added. The solution was brought up to volume or weight with distilled water under agitation. Results: pH = 5.2; Osmolality = 150 mOsm.
EXAMPLE 2 Further formulations of Ciprofloxacin and Sulfoalkylether Cyclodextrin
Appropriate amounts of SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 1 %> to about 30%. While the aqueous CD solution was being stirred, ciprofloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stined until it became clear. No viscosity enhancing agents, preservatives or other pharmaceutically acceptable ingredients were added. The solution was brought up to volume or weight with distilled water under agitation.
EXAMPLE 3 Formulation of Ciprofloxacin and Sulfoalkylether
Cyclodextrin with Polymer and Preservative
Appropriate amounts of SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stined, ciprofloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stined until it became clear. Water soluble polymer, hydroxypropylmethylcellulose (E50), was added to the solution such that the concentration of the polymer is about 0.1% to 10%.
Preservative, chlorobutanol, was added such that its concentration is between 0.1 % to
1%. Tonicity modifiers such as sodium chloride are added, if needed. The solution was brought up to volume or weight with distilled water under agitation.
EXAMPLE 4 Freeze-dried formulation of Ciprofloxacin and Sulfoalkylether Cyclodextrin with Polymer and Preservative
Appropriate amounts of SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stined, ciprofloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stined until it became clear. Water soluble polymer, hydroxypropylmethylcellulose (E50), was added to the solution such that the concentration of the polymer is about 0.1% to 10%. Preservative, chlorobutanol, was added such that its concentration is between 0.1% to 1%. The solution was brought up to volume or weight with distilled water under agitation. Tonicity modifiers such as sodium chloride are added, if needed. This solution was filtered through a filter of 0.45 μm or lower porosity and freeze-dried.
EXAMPLE 5 Appropriate amounts of SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stined, ciprofloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stined until it became clear. A water soluble polymer, hydroxypropylmethylcellulose (viscosities ranging from 2 cps to 40, 000 cps), was added to the solution such that the concentration of the polymer is about 0.1% to 10%. A preservative, chlorobutanol, is added such that its concentration is between 0.1% to 1%. Tonicity modifiers such as sodium chloride are added, if needed. The solution is brought up to volume or weight with distilled water under agitation. This solution is filtered through a filter of 0.45 μm or lower porosity and further processed to obtain a liquid or solid formulation. EXAMPLE 6 Ciprofloxacin HPLC Method This example describes methods for the analysis of ciprofloxacin content in compositions of the invention by high performance liquid chromatography (HPLC).
Column: Agilent Zorbax Eclipse XDB-C18, 4.6xl50mm, 3.5μ Mobile Phase: 87:13, 0.025 M phosphoric acid pH 3.0: Acetonitrile Injection volume: 10 μL UV detection @ 278nm Flow rate: 1 mL/min Column temperature: 40 °C
Precision: Response of a 0.05 mg/mL solution %RSD (n=10) = 0.6%
Accuracy:
Compared to a second standard solution of same concentration = 98.6%
Linearity:
Performed 10 injections of Ciprofloxacin standard 0.05 mg/mL at 5.0, 7.5, 10, 12.5 and 15.0 μL volumes, which corresponded to 0.25, 0.375, 0.5, 0.625, and 0.75 μg of
Ciprofloxacin loaded onto the column. These values conesponded to 50 to 150%) of the nominal concentration of 0.05 mg/mL. The %RSDι0 of each set of injections were all < 1.3%.
LOD/LOQ:
Performed 6 injections of solutions of ciprofloxacin ranging in concentrations from 0.0001 to 0.01 mg/mL in the attempt to get an estimation of LOD/LOQ.
LOD = 10 (SD/S)
10 μl of 0.0001 mg/mL (0.001 μg column load) X6 = 18373, SD = 1059 LOQ = 10 (1059 / 7.0 x 106) = 0.0015 μg
LOD = 3.3 (1059 / 7.0 x 106) = 0.0005 μg
EXAMPLE 7 Degradation Study The purpose of this example was to demonstrate that the HPLC assay described above can also be utilized as stability indicating assay method. Procedure: Purposely cause degradation of a solution of
Ciprofloxacin by exposing a solution of the active to 2 M methanolic acid (HC1 in methanol) and 0.2 M NaOH in water under ambient and heated conditions. Combine 1.0 mg/mL of Ciprofloxacin with 2 M methanolic acid and also combine 1.0 mg/mL of Ciprofloxacin with 0.2 M NaOH in water to get a final concentration of 0.5 mg/mL Ciprofloxacin. Store solutions at ambient conditions and at 80 °C for approximately 24 hours. Control samples were also prepared by diluting 1.0 mg/mL of Ciprofloxacin with the appropriate amount of solvent (either methanol or water) and will also be stored under ambient and heated conditions. Method: Same as assay method. Results: Under the conditions of heating with or without base or acid, new peaks were detected at the following relative retention times (RRT's, relative to the main ciprofloxacin peak). 0.27, 0.36, 0.55, 0.60, 0.68 and 0.72.
Conclusion: The results of the degradation studies show the presence of additional, well-resolved peaks indicating that this method can be utilized for both assay and stability indicating purposes.
EXAMPLE 8 Formulation of Gatifloxacin and Sulfoalkylether Cyclodextrin
The following formulation was made according to the following procedure. SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 3%. While the aqueous CD solution was being stined,
Gatifloxacin, in amounts that would eventually provide a 6 mg/mL solution, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of Gatifloxacin). The solution was stirred until it became clear. No viscosity enhancing agents, preservatives or other pharmaceutically acceptable ingredients were added. The solution was brought up to volume or weight with distilled water under agitation. Results: pH = ca. 6; Osmolality = ca.150 mOsm.
EXAMPLE 9 Formulation of Gatifloxacin and Sulfoalkylether Cyclodextrin
Appropriate amounts of SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stirred, Gatifloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stined until it became clear. No viscosity enhancing agents, preservatives or other pharmaceutically acceptable ingredients were added. The solution was brought up to volume or weight with distilled water under agitation.
EXAMPLE 10 Formulation of Gatifloxacin and Sulfoalkylether Cyclodextrin with Polymer and Preservative
Appropriate amounts of SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stirred, Gatifloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of Gatifloxacin). The solution was stined until it became clear. Water soluble polymer, hydroxypropylmethyl cellulose, was added to the solution such that the concentration of the polymer is about 0.1%) to 10%. Preservative, chlorobutanol, was added such that its concentration is between 0.1% to 1%. Tonicity modifiers such as sodium chloride are added, if needed. The solution was brought up to volume or weight with distilled water under agitation. EXAMPLE 11
Formulation of Gatifloxacin. Hydrocortisone. Hydroxypropyl Cyclodextrin and
Sulfoalkylether Cyclodextrin with Polymer and Preservative
Appropriate amounts of SBE7-β-CD and HPCD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stined, Gatifloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of ciprofloxacin). The solution was stined until it became clear. This followed by the dispersion of hydrocortisone, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL. After the solution clarifies, water soluble polymer, hydroxypropylmethylcellulose, was added to the solution such that the concentration of the polymer is about 0.1% to 10%.
Preservative, chlorobutanol, was added such that its concentration is between 0.1% to 1%. The solution was brought up to volume or weight with distilled water under agitation. Tonicity modifiers such as sodium chloride are added, if needed. This solution was filtered through a filter of 0.45 μm or lower porosity and further processed to obtain a solid or liquid formulation.
EXAMPLE 12
Appropriate amounts of HPCD and SBE7-β-CD was dissolved in distilled, deionized water to obtain a concentration of about 1 % to about 30%. While the aqueous CD solution was being stined, Gatifloxacin, in amounts that would eventually provide a concentration between 1 mg/mL and 60 mg/mL, was dispersed into it. This was followed by the addition of citric acid (0.1 eq to 10.0 eq in relation to molar concentration of Gatifloxacin). The solution was stined until it became clear. After dispersion of hydrocortisone and clarification of the solution, water soluble polymer, hydroxypropylmethyl cellulose (viscosities ranging from 2 cps to 40, 000 cps), was added to the solution such that the concentration of the polymer is about 0.1% to 10%). Preservative, chlorobutanol, was added such that its concentration is between 0.1 % to 1%>. Tonicity modifiers such as sodium chloride are added, if needed. The solution was brought up to volume or weight with distilled water under agitation. This solution was filtered through a filter of 0.45 μm or lower porosity and further processed to obtain a liquid or solid formulation.
EXAMPLE 13 Gatifloxacin HPLC Method Column: Agilent Zorbax Eclipse XDB-C18, 4.6x150mm, 3.5μ
Mobile Phase: 85:15, 0.025 M phosphoric acid pH 3.0 (with TEA): Acetonitrile Injection volume: 10 μL UV detection @ 293 nm Flow rate: 1 mL/min Column Temperature: 40 °C
Precision
A 0.1005mg/mL Standard Solution had a response of 0.34AU. There was 0.1 %RSD between ten injections.
Accuracy
Compared to a second standard solution, the control fell between 99.8-100.2% over 7
(0, 1, 5, 7) days.
Linearity
Five Gatifloxacin standard solutions were prepared of concentration 0.050025,
0.07575, 0.1005, 0.1255, and 0.1515mg/mL and injected ten times each. These values conesponded to 50 to 150% of the nominal concentration of 0.1 mg/mL. The
%RSDιo of each set of injections were all <0.2%.
LOD/LOQ
Performed 6 injections of Ciprofloxacin ranging from 0.00002367 to 0.0007575 mg/mL in the attempt to get an estimation of LOD/LOQ.
LOD = 10 (SD/S) LOQ= 3.3(SD/S) Used the 0.00002367mg/mL (0.0002367 μg column load) X6 =2406, SD = 275
LOQ = 10 (275/ 5.0 x 106) = 0.00055 μg LOD = 3.3 (275/ 5.0 x 106) = 0.0001815 μg
EXAMPLE 14 Soluble Polymers and Corneal Precipitation
The prevention of corneal precipitation with a soluble polymer such as HPMC is a further object of the present invention. At pH's higher than the pKa of fluoroquinolones, HPMC, and to a very slightly reduced degree PVA, is able to prevent corneal precipitation even at high concentrations, in vitro. These concentrations are far higher than the solubility of fluoroquinolones in solutions of HPMC and PVA at concentrations in the formulations.. This result is particularly unexpected since various published reports have stated that in order for a water soluble polymer to co-solubilize a hydrophobic drug in the presence of a cyclodextrin, micelle formation is necessary (A. M. Sigurdardottir et al, International Journal of Pharmaceutics, 126, 1995, p73-78; J. K. Kristinsson et al, Investigations in Ophthalmology Visual Sciences, 37, 1996, pi 199-1203; Thorsteinn Loftsson et al, Advanced Drug Delivery Reviews, 36 (1999), p59-79). The reports further state that such micelle formation of the cyclodextrin and polymer is possible only by aggressive processing such as autoclaving at 120 °C or sonication at 80 °C for hours. Our process involves nothing but benign agitation.
Figure 1 shows that a combination formulation (Ciprofloxacin/ Hydrocortisone, 0.6%/0.6%) with all ingredients including HPMC, shows essentially no corneal precipitation in vitro. This is infened from the fact that the total and soluble concentrations are same, as the pH of the tear film gets adjusted to normal lachrymal pH as a function of time, within experimental enor. While this in vitro tear turn-over study simulated first-order nasolachrymal drainage and equilibration to lachrymal pH as a function of time, it does not simulate other important parameters such as increase in residence time in the eye as the viscosity of the formulation is increased and induced lachrymation as a function of the formulation. Figure 2 shows that a control combination formulation
(Ciprofloxacin/ Hydrocortisone, 0.6%/0.6%) with all ingredients except HPMC leads to corneal precipitation in vitro. This is infened from the fact that at pH's higher than 6.1, the total concentration is much higher than the soluble concentration (as high as 200%). It is visually obvious that precipitation is commenced at pH's higher than the pKa, in formulations without the "pH independent precipitation inhibitor". The solution becomes very cloudy and the drug can be visually observed as fine particles suspended in solution. The experimental logic and design has already been published for these in vitro tear turn-over experiments (B. A. Firestone et al, International Journal of Pharmaceutics, 164 (1998), pi 19-128).
Figure 3 shows that CILOXAN® (0.3% Ciprofloxacin Hydrochloride) when exposed to a photostability chamber (ICH conditions), undergoes substantial degradation over a 24 hr period. The figure also shows that 0.3%» ciprofloxacin formulation composed according to the inventions given above are considerably more stable than CILOXAN® itself.
Figure 4 shows that CILOXAN® (0.3% Ciprofloxacin Hydrochloride) when exposed to a photostability chamber (ICH conditions), undergoes substantial degradation over a 24 hr period. The figure also shows that a triply potent ciprofloxacin formulation composed according to the inventions is considerably more stable than than CILOXAN® itself.
Figure 5 shows the photo stability of ciprofloxacin and gatifloxacin in ciprofloxacin/hydrocortisone and gatifloxacin/hydrocortisone combination formulations respectively.
Figure 6 shows that formulations that are part of these inventions are stable on long-term storage even under accelerated stability conditions. No precipitation of the active was observed throughout.
It is fairly well documented than fluoroquinolone solutions such as ciprofloxacin solutions are stable at acidic pH's (<5) and that considerable degradation occurs at higher pH's (K Torniainen et al, International Journal of Pharmaceutics, 132, 1996, p53-61; K Torniainen et al, Journal of Pharmaceutical and Biomedical Analysis, 16, 1997, p439-445; K Torniainen et al, Journal of Pharmaceutical and Biomedical Analysis, 15, 1997, p887-894). Whilst no buffering agents have been added to increase stability or adjust buffering capacity, our invention showed unexpected buffering. The buffer capacity for a fonnulations are generally in the range of 0.001 or higher. It is believed that, in addition to the formation of an inclusion complex, the formulations mentioned in these inventions are further stabilized by this coincidental buffering. The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is described by the following claims, with equivalents of the claims to be included therein.

Claims

1. An aqueous pharmaceutical composition comprising: from 1 to 100 mg/mL of a fluoroquinolone active agent; from 0 to 100 mg/mL of a steroidal or non-steroidal anti-inflammatory agent; from 1 to 50% by weight of cyclodextrin; from 0.1 to 25 molar equivalents of a hydroxy acid; from 0 to 20% by weight of a co-solibilizer; and water to balance, said formulation having a pH between 4 and 7.
2. The composition according to claim 1, wherein said cyclodextrin is selected from the group consisting of α cyclodextrins, β cyclodextrins, γ cyclodextrins, and δ cyclodextrins.
3. The composition according to claim 1, wherein said cyclodextrin is selected from the group consisting of sulfoalkylether cyclodextrins and hydroxyalkyl cyclodextrins.
4. The composition according to claim 1, wherein said hydroxy acid is selected from the group consisting of citric acid, ascorbic acid, malic acid, and tartaric acid.
5. The composition according to claim 4, further comprising from 0.001 to 2 percent by weight of a preservative. "
6. The composition according to claim 1, further comprising a preservative selected from the group consisting of chlorobutanol, sorbic acid, and EDTA.
7. The composition according to claim 1, further comprising: from 0.05 to 5 %ι by weight of a soluble polymer.
8. The composition according to claim 7, wherein said soluble polymer is selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, and poloxamers.
9. The composition according to clainm 1, wherein said fluoroquinolone is selected from the group consisting of Gatifloxacin, Moxifloxacin, Sitafloxacin, Lomefloxacin, Grepafloxacin, Gemifloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Trovafloxacin, Ciprofloxacin and combinations thereof.
10. The composition according to claim 1, wherein said steroidal or non-steroidal anti-inflammatory compound is a steroidal compound and is selected from the group consisting of cortisone, hydrocortisone, corticosterone, deoxycorticosterone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexamethazone, fludrocortisone, and combinations thereof.
11. The composition according to claim 1 , wherein said steroidal or non-steroidal anti-inflammatory compound is a non-steroidal compound and is selected from the group consisting of aspirin, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nambumetone, acetaminophen, nimesulide, NS-398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-
58125, etoricoxib, RS-57067, L-748780, L-761066, APHS, etodolac, meloxicam, and S-2474, and combinations thereof.
12. A method of treating a bacterial infection of an eye of a subject in need thereof, comprising topically administering a formulation according to claim 1 to the eye of said subject in an amount effective to treat said bacterial infection.
13. A pharmaceutical formulation comprising : from 1 to 100 mg/mL of a fluoroquinolone active agent; from 0 to to 100 mg/mL of a steroidal or non-steroidal anti-inflammatory agent; from 1 to 50%) by weight of cyclodextrin; from 0.1 to 25 molar equivalents of a hydroxy acid.
14. A pharmaceutical formulation according to claim 13 in lyophilized form which when reconstituted with water produces an aqueous pharmaceutical composition having a pH between 4.5 and 7 and comprising: from 1 to 100 mg/mL of a fluoroquinolone active agent; from 1 to 50% by weight of cyclodextrin; from 0.1 to 25 molar equivalents of a hydroxy acid; and water to balance.
15. The composition according to claim 13, wherein said cyclodextrin is selected from the group consisting of α cyclodextrins, β cyclodextrins, γ cyclodextrins, and δ cyclodextrins.
16. The composition according to claim 13, wherein said cyclodextrin is selected from the group consisting of sulfoalkylether cyclodextrins and hydroxyalkyl cyclodextrins.
17. The composition according to claim 13, wherein said hydroxy acid is selected from the group consisting of citric acid, ascorbic acid, malic acid, and tartaric acid.
18. The composition according to claim 13, further comprising from 0.001 to 2 percent by weight of a preservative.
19. The composition according to claim 18, said preservative selected from the group consisting of chlorobutanol, sorbic acid, and EDTA.
20. The composition according to claim 14, further comprising: from 0.05 to 5 % by weight of a soluble polymer.
21. The composition according to claim 21, wherein said soluble polymer is selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, and poloxamers.
22. The composition according to clainm 13, wherein said fluoroquinolone is selected from the group consisting of Gatifloxacin, Moxifloxacin,
Sitafloxacin, Lomefloxacin, Grepafloxacin, Gemifloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Trovafloxacin, Ciprofloxacin and combinations thereof.
23. The composition according to claim 13, wherein said steroidal or non- steroidal anti-inflammatory compound is a steroidal compound and is selected from the group consisting of cortisone, hydrocortisone, corticosterone, deoxycorticosterone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexamethazone, fludrocortisone, and combinations thereof.
24. The composition according to claim 13, wherein said steroidal or non- steroidal anti-inflammatory compound is a non-steroidal compound and is selected from the group consisting of aspirin, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nambumetone, acetaminophen, nimesulide, NS-398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-58125, etoricoxib, RS-57067, L-748780, L-761066, APHS, etodolac, meloxicam, and S-2474, and combinations thereof, thereof.
25. In a method of topically applying a pharmaceutical composition containing an active compound to the eye of a subject in need thereof, which active compound precipitates from said composition on the cornea of said subject, the improvement comprising: including a soluble polymer in said composition in an amount effective to reduce the precipitation of said active compound on the cornea of said subject.
26. The method according to claim 25, wherein said soluble polymer is selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinylpynolidone, and polyvinyl alcohol, and poloxamers.
27. The method according to claim 25, wherein said active compound is a fluoroquinolone.
28. The method according to claim 25, said pharmaceutical composition further comprising a steroidal or non-steroidal anti-inflammatory compound.
29. In a topical pharmaceutical composition containing an active compound used to topically apply said active compound to the eye of a subject in need thereof, which active compound precipitates from said composition on the cornea of said subject, the improvement comprising: including from 0.05 to 5% by weight of a soluble polymer in said composition in an amount effective to reduce the precipitation of said active compound on the cornea of said subject.
30. The composition according to claim 29, wherein said soluble polymer is selected from the group consisting of methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, and polyvinyl alcohol, and poloxamers.
31. The composition according to claim 29, wherein said active compound is a fluoroquinolone.
32. The composition according to claim 29, said composition further comprising a steroidal or non-steroidal anti-inflammatory compound.
PCT/NL2004/000252 2003-04-14 2004-04-14 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid Ceased WO2004089418A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04727461A EP1613356A1 (en) 2003-04-14 2004-04-14 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxy acid
MXPA05011115A MXPA05011115A (en) 2003-04-14 2004-04-14 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid.
JP2006507868A JP2006523687A (en) 2003-04-14 2004-04-14 I. A. Aqueous formulation of fluoroquinolone with cyclodextrin and hydroxy acid, pH 4-7
US10/552,477 US20070049552A1 (en) 2003-04-14 2004-04-14 Fluoroquinolone formulations and methods of making and using the same
CA002522115A CA2522115A1 (en) 2003-04-14 2004-04-14 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/413,045 2003-04-14
US10/413,045 US20040202687A1 (en) 2003-04-14 2003-04-14 Ciprofloxacin formulations and methods of making and using the same
US10/817,507 2004-04-02
US10/817,507 US20050085446A1 (en) 2003-04-14 2004-04-02 Fluoroquinolone formulations and methods of making and using the same

Publications (1)

Publication Number Publication Date
WO2004089418A1 true WO2004089418A1 (en) 2004-10-21

Family

ID=33161981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2004/000252 Ceased WO2004089418A1 (en) 2003-04-14 2004-04-14 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid

Country Status (6)

Country Link
US (1) US20050085446A1 (en)
EP (1) EP1613356A1 (en)
JP (1) JP2006523687A (en)
CA (1) CA2522115A1 (en)
MX (1) MXPA05011115A (en)
WO (1) WO2004089418A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090646A1 (en) * 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
WO2008044733A1 (en) 2006-10-12 2008-04-17 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid preparation having improved intraocular gatifloxacin penetration
JP2008535925A (en) * 2005-04-11 2008-09-04 アボット・ラボラトリーズ Pharmaceutical composition having improved dissolution profile of poorly soluble drugs
WO2009104045A1 (en) * 2008-02-22 2009-08-27 S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. Ophthalmic gemifloxacin compositions for the treatment of ocular infections
JP2009531451A (en) * 2006-03-28 2009-09-03 ジャヴェリン ファーマシューティカルズ インコーポレイテッド Low dose non-steroidal anti-inflammatory drug and β-cyclodextrin combination
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
EP2149374A4 (en) * 2007-05-28 2010-12-08 World Trade Imp Export Wtie Ag Pharmaceutical composition comprising the combinaton of the anti-microbial agent ciprofloxacin and the antioxidant agent ascorbic acid for the treatment of urinary infections
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
CN103110575A (en) * 2013-03-07 2013-05-22 宁夏康亚药业有限公司 Meloxicam eye drop as well as preparation method and application thereof
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
EP2373166A4 (en) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc ANTIMICROBIAL COMPOSITIONS
WO2015007759A1 (en) * 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015007760A1 (en) * 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US9107952B2 (en) 2006-11-07 2015-08-18 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US10172804B2 (en) 2013-12-04 2019-01-08 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US10537588B2 (en) 2004-03-25 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
US11413285B2 (en) 2004-03-25 2022-08-16 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009836A1 (en) * 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
CA2679626C (en) * 2007-03-21 2012-10-23 Bausch & Lomb Incorporated Fluoroquinolones for treating, reducing, ameliorating, or preventing infections caused by antibacterial-drug resistant bacteria
EP2260847A4 (en) * 2008-03-31 2011-12-28 Kyorin Seiyaku Kk WATER-CONTAINING LIQUID WITH GATIFLOXACIN
MX342183B (en) * 2008-09-09 2016-09-20 Allergan Inc Ophthalmic suspension for ocular use.
RU2435583C1 (en) * 2010-07-20 2011-12-10 Владимир Николаевич Быков Pharmaceutical composition with antibacterial activity
US20140377355A1 (en) * 2013-06-19 2014-12-25 Professional Compounding Centers Of America Levofloxacin Inhalation Composition
US20140377356A1 (en) * 2013-06-19 2014-12-25 Professional Compounding Centers Of America (Pcca) Inhalation Composition for Treating Respiratory Tract Infections
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6358868B2 (en) * 2014-06-17 2018-07-18 Ｄｓファーマアニマルヘルス株式会社 Pharmaceutical composition containing orbifloxacin
CA3023243C (en) * 2016-05-06 2020-01-21 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions and methods for fabricating thereof
CA3074326A1 (en) * 2017-09-01 2019-03-07 Murray & Poole Enterprises, Ltd. Methods and compositions for the treatment of ophthalmic conditions
US10744153B1 (en) * 2019-07-01 2020-08-18 Cloudbreak Therapeutics Llc Compositions and methods for treating meibomian gland dysfunction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447351A1 (en) * 1990-03-07 1991-09-18 Children's Medical Center Corporation Medicament for retaining ophthalmological agents in ocular tissues and method for its production
EP0694310A1 (en) * 1993-04-16 1996-01-31 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
EP1312366A1 (en) * 2000-08-08 2003-05-21 Wakamoto Pharmaceutical Co., Ltd. Aqueous pharmaceutical compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704907A1 (en) * 1987-02-17 1988-08-25 Bayer Ag TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS
IT1263831B (en) * 1993-01-29 1996-09-04 Paolo Chiesi MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSTITUTED BY A BASIC-TYPE DRUG, AN ACID AND A CYCLODEXTRINE
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
KR100595956B1 (en) * 1998-08-21 2006-07-03 센주 세이야꾸 가부시키가이샤 Aqueous Liquid Pharmaceutical Compositions
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
JP2003510263A (en) * 1999-09-24 2003-03-18 アルコン，インコーポレイテッド Topical suspension formulation containing ciprofloxacin and dexamethasone
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447351A1 (en) * 1990-03-07 1991-09-18 Children's Medical Center Corporation Medicament for retaining ophthalmological agents in ocular tissues and method for its production
EP0694310A1 (en) * 1993-04-16 1996-01-31 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
EP1312366A1 (en) * 2000-08-08 2003-05-21 Wakamoto Pharmaceutical Co., Ltd. Aqueous pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAKAWA T ET AL: "Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-beta-cyclodextrin", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 86, no. 1, 9 January 2003 (2003-01-09), pages 101 - 113, XP004399002, ISSN: 0168-3659 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537588B2 (en) 2004-03-25 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
US11413285B2 (en) 2004-03-25 2022-08-16 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure
JP2013121976A (en) * 2005-04-11 2013-06-20 Abbott Lab Pharmaceutical composition having improved dissolution profile for poorly soluble drug
JP2008535925A (en) * 2005-04-11 2008-09-04 アボット・ラボラトリーズ Pharmaceutical composition having improved dissolution profile of poorly soluble drugs
WO2007090646A1 (en) * 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
AU2007213983B2 (en) * 2006-02-10 2012-09-20 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
JP2009531451A (en) * 2006-03-28 2009-09-03 ジャヴェリン ファーマシューティカルズ インコーポレイテッド Low dose non-steroidal anti-inflammatory drug and β-cyclodextrin combination
US8946292B2 (en) 2006-03-28 2015-02-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2008044733A1 (en) 2006-10-12 2008-04-17 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid preparation having improved intraocular gatifloxacin penetration
EP2078526A4 (en) * 2006-10-12 2011-08-10 Kyorin Seiyaku Kk AQUEOUS LIQUID PREPARATION WITH ENHANCED INTRAOCULAR GATIFLOXACIN PENETRATION
US9107952B2 (en) 2006-11-07 2015-08-18 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US10639305B2 (en) 2006-11-07 2020-05-05 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US9616134B2 (en) 2006-11-07 2017-04-11 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
EP2149374A4 (en) * 2007-05-28 2010-12-08 World Trade Imp Export Wtie Ag Pharmaceutical composition comprising the combinaton of the anti-microbial agent ciprofloxacin and the antioxidant agent ascorbic acid for the treatment of urinary infections
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
WO2009104045A1 (en) * 2008-02-22 2009-08-27 S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. Ophthalmic gemifloxacin compositions for the treatment of ocular infections
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
CN103705942B (en) * 2008-11-15 2016-08-24 麦林塔医疗有限公司 Antimicrobial compositions
US12138257B2 (en) 2008-11-15 2024-11-12 Melinta Subsidiary Corp. Antimicrobial compositions
EP2373166A4 (en) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc ANTIMICROBIAL COMPOSITIONS
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP2965761A4 (en) * 2013-03-07 2016-02-24 Kangya Of Ningxia Pharmaceuticals Co Ltd OPHTHALMIC DROPS TO THE MELOXICAM AND METHOD OF PREPARATION AND USE THEREOF
CN103110575A (en) * 2013-03-07 2013-05-22 宁夏康亚药业有限公司 Meloxicam eye drop as well as preparation method and application thereof
CN103110575B (en) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 Meloxicam eye drop as well as preparation method and application thereof
CN105377235A (en) * 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 Liquid aqueous pharmaceutical composition containing preserved etherified cyclodextrin derivative
US11185590B2 (en) 2013-07-19 2021-11-30 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US12357696B2 (en) 2013-07-19 2025-07-15 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015007759A1 (en) * 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
AU2014292086B2 (en) * 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EA034430B1 (en) * 2013-07-19 2020-02-06 Бёрингер Ингельхайм Ветмедика Гмбх LIQUID WATER PHARMACEUTICAL COMPOSITION WITH PRESERVATIVES CONTAINING ETERIFIED DERIVATIVES CYCLODEXTRIN
US10071162B2 (en) 2013-07-19 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015007760A1 (en) * 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP3865120A1 (en) 2013-07-19 2021-08-18 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US10172804B2 (en) 2013-12-04 2019-01-08 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US12257350B2 (en) 2013-12-04 2025-03-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US12011441B2 (en) 2016-04-06 2024-06-18 Boehringer Ingelheim Vetmedica Gmbh Pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US20210038612A1 (en) * 2018-04-03 2021-02-11 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
US12042500B2 (en) 2018-04-03 2024-07-23 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics

Also Published As

Publication number Publication date
EP1613356A1 (en) 2006-01-11
CA2522115A1 (en) 2004-10-21
JP2006523687A (en) 2006-10-19
MXPA05011115A (en) 2006-05-19
US20050085446A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
US20050085446A1 (en) Fluoroquinolone formulations and methods of making and using the same
KR101767689B1 (en) Antimicrobiral compositions
JP4334229B2 (en) Formulation containing propofol and sulfoalkyl ether cyclodextrin
CN107261152B (en) Method for preserving injectable pharmaceutical compositions comprising cyclodextrins and hydrophobic drugs
JP6272475B2 (en) Liquid aqueous pharmaceutical composition containing antiseptic etherified cyclodextrin derivative
US20070049552A1 (en) Fluoroquinolone formulations and methods of making and using the same
CN102935080A (en) Bendamustine cyclopolysaccharide compositions
CN101657203B (en) Compositions and delivery methods of anticancer drugs
KR20190100237A (en) Otic compositions useful for the treatment of infections of the internal and external ear in mammals
KR102762379B1 (en) Ophthalmic Composition
US20040202687A1 (en) Ciprofloxacin formulations and methods of making and using the same
EP2994109B1 (en) Aqueous ophthalmic formulations based on azithromycin
JP2005520856A (en) Eplerenone formulation stable during storage
CN106687179A (en) Methods for treating infections
HK1213821B (en) Antimicrobial compositions
HK1196530A (en) Antimicrobial compositions
HK1196530B (en) Antimicrobial compositions
JP2005527615A (en) A novel formulation for parenteral application of sodium channel blockers
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004727461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2522115

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/011115

Country of ref document: MX

Ref document number: 2006507868

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004727461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007049552

Country of ref document: US

Ref document number: 10552477

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10552477

Country of ref document: US